Comparison of the cost of illness of primary liver cancer between Japan and Taiwan

Yinghui Wu (), Kunichika Matsumoto (), Ya-Mei Chen (), Yu-Chi Tung (), Tzu-Ying Chiu () and Tomonori Hasegawa ()
Additional contact information
Yinghui Wu: Shanghai Jiao Tong University
Kunichika Matsumoto: Toho University School of Medicine
Ya-Mei Chen: National Taiwan University
Yu-Chi Tung: National Taiwan University
Tzu-Ying Chiu: Graduate Institute of Long-term Care, Tzu Chi University of Science and Technology
Tomonori Hasegawa: Toho University School of Medicine

Health Economics Review, 2020, vol. 10, issue 1, 1-7

Abstract: Abstract Background Primary liver cancer (PLC) is the fifth and second leading cause of death in Japan and Taiwan, respectively. The aim of this study was to compare the economic burden of PLC between the two countries using the cost of illness (COI) method and identify the key factors causing the different trends in the economic burdens of PLC. Materials and methods We calculated the COI every 3 years using governmental statistics of both countries (1996–2014 data for Japan and 2002–2014 data for Taiwan). The COI was calculated by summing the direct costs, morbidity costs, and mortality costs. We compared the COIs of PLC in both countries at the USD-based cost. The average exchange rate during the targeted years was used to remove the impact of foreign exchange volatility. Results From 1996 to 2014, the COI exhibited downward and upward trends in Japan and Taiwan, respectively. In Japan, the COI in 2014 was 0.70 times the value in 1996, and in Taiwan, the COI in 2014 was 1.16 times greater than that in 1996. The mortality cost was the greatest contributor in both countries and had the largest contribution ratio to the COI increase in Japan. However, the direct cost in Taiwan had the largest contribution ratio to the COI decrease. Conclusions To date, the COI of PLC in Japan has continuously decreased, whereas that in Taiwan has increased. Previous health policies and technological developments are thought to have accelerated the COI decrease in Japan and are expected to change the trend of COI of PLC, even in Taiwan.

Keywords: Cost of illness; Health policy; Liver neoplasms; Medical economics; Public health (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-020-00296-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:10:y:2020:i:1:d:10.1186_s13561-020-00296-7

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-020-00296-7

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().